BNT326-02: A Clinical Trial to Test if an Investiga-tional Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Can-cer (NSCLC)

This is a multi-site, open-label, dose-finding study, consisting of Parts 1, 2a, and 2b to investigate the combination of BNT326 with pu-mitamig (also known as BNT327 or PM8002) in participants with relapsed, progressive as well as treatment-naïve, ad-vanced/metastatic non-small cell lung cancer (NSCLC).

This study will enroll adult participants with histologically or cytologi-cally confirmed NSCLC that is advanced (i.e., either metastatic or recurrent tumors with no known curative treatment available).